Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31,...

Related Keywords

United States ,United Kingdom ,Neurocrine Biosciences ,Sosei Heptares ,Neurocrine Bioscience ,Kevin Gorman ,Neurocrine Biosciences Inc ,Sosei Group Corporation ,Voyager Therapeutics Inc ,Linkedin ,Mitsubishi Tanabe Pharma Corporation ,Drug Administration ,Takeda Pharmaceutical Company ,Nasdaq ,Xenon Pharmaceuticals ,Diurnal Group ,Fourth Quarter Net Product Sales ,Product Sales Guidance ,Pediatric Registrational Studies ,Congenital Adrenal ,Online Data ,Clinical Programs ,Congenital Adrenal Hyperplasia ,Focal Onset Seizure ,Major Depressive Disorder Expected ,Second Half ,Chief Executive Officer ,Quarterand Fiscal ,Product Sales ,Commercial Highlights ,Quarter Financial Highlights ,Process Research ,New Drug Application ,Prescription Drug User Fee Act ,Voyager Therapeutics ,Hart Scott Rodino Antitrust Improvements Act ,Operating Expense Guidance ,Tardive Dyskinesia Only ,Net Product Sales ,Pipeline Milestones ,Adrenal Hyperplasia ,Line Registrational Data ,Onset Seizure ,Line Phase ,Major Depressive ,Least One Phase ,Vesicular Monoamine Transporter ,Corticotropin Releasing Factor Type ,Sodium Channel ,Orphang Protein Coupled ,Biosciences Partners ,East Asia ,Takeda Pharmaceutical Company Limited ,Sosei Group ,Webcast Today ,Quarterly Report ,Nc ,